C4BPB: Potential Drug Target for Cancer and Inflammation (G725)

Target Name: C4BPB

NCBI ID: G725

C4BPB

C4BPB: Potential Drug Target for Cancer and Inflammation

C4BPB, also known as C4b-binding protein beta chain (isoform 1), is a protein that is expressed in various tissues throughout the body, including the liver, spleen, and bone marrow. It is a member of the BCL-2 (B cell lymphoma 2) family and is known for its ability to interact with the protein C4, which is also known as complement component 4.

C4BPB is a 14-kDa protein that consists of two distinct chains, an N-terminal chain of 115 amino acids and a C-terminal chain of 185 amino acids. The N-terminal chain has a putative transmembrane region and is involved in the interaction with the N-terminal domain of C4. The C-terminal chain has a single extracellular domain and is involved in the interaction with C4.

C4BPB has been shown to play a role in the regulation of various cellular processes, including cell proliferation, apoptosis, and inflammation. For example, studies have shown that overexpression of C4BPB can promote the growth and survival of human cancer cells, while inhibition of C4BPB has been shown to inhibit the growth and survival of cancer cells.

In addition to its role in cancer, C4BPB has also been shown to be involved in the regulation of inflammation. Studies have shown that C4BPB can interact with various immune cells, including natural killer cells and T cells, and can modulate their activity. This suggests that C4BPB may be a potential drug target for the treatment of inflammatory diseases.

C4BPB has also been shown to be involved in the regulation of cellular signaling pathways. For example, studies have shown that C4BPB can interact with the protein PyR, which is involved in the PyR-C4 complex, a signaling pathway that is involved in the regulation of cell proliferation. This suggests that C4BPB may be a potential drug target for the treatment of various diseases that are characterized by uncontrolled cell growth, such as cancer.

Despite its potential as a drug target, C4BPB has not yet been shown to be a reliable biomarker for any disease. This is likely due to the fact that C4BPB is expressed in various tissues throughout the body and its levels can vary depending on the specific cell type and the experimental context. Additionally, the complexity of C4BPB's structure and function may make it difficult to use it as a reliable biomarker.

In conclusion, C4BPB is a protein that has been shown to play a role in various cellular processes, including cancer and inflammation. Its potential as a drug target makes it an attractive target for the development of new treatments for these diseases. Further research is needed to fully understand the role of C4BPB in cellular signaling pathways and to determine its potential as a biomarker.

Protein Name: Complement Component 4 Binding Protein Beta

Functions: Controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. It also interacts with anticoagulant protein S and with serum amyloid P component. The beta chain binds protein S

The "C4BPB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C4BPB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets